Tom Payne

NIHR Clinical Lecturer in Neurology at the Sheffield Institute for Translational Neuroscience (SITraN). Researching Parkinson's Disease. All thoughts my own

[Charalampos Tzoulis @chtzoulis]

Is mitochondrial pathology universal in idiopathic Parkinson's disease? We find widespread mitochondrial pathology in the brain of ~25% of individuals with PD, linked to a non-tremor dominant motor phenotype. Could this be a "mitoPD" subtype?
https://t.co/xXlmN7Ziui

[Tom Payne @NeuroPayne]

Thank you and the wider team for having me!

[Sophie Voyce (OT) she/her @sv_voyce]

Really interesting update about Parkinson's research from @NeuroPayne here at Derby. So much important work being done- Thank you! 👏

[Tom Payne @NeuroPayne]

Really enjoyed the day lots of interesting talks and exciting research happening in our @SheffieldBRC and @CRFSheffield

[NIHR Sheffield Biomedical Research Centre @SheffieldBRC]

We're kicking off our second session of the day with talks from selected abstracts from across our infrastructures.

Here is Dr Tom Payne discussing the UP Study!

[Tom Payne @NeuroPayne]

On #WorldParkinsonsDay I'm very proud to be part of a team and institute working towards effective disease modifying treatments for Parkinson's

[Neuroscience Institute @neuroshef]

Each day, 80 people in the UK are newly diagnosed with #ParkinsonsDisease which affects over six million people globally. There is currently no cure. Working closely with patients, our researchers are transforming the understanding of Parkinson’s disease. 🧵 #WorldParkinsonsDay

[Tom Payne @NeuroPayne]

@foltynie @ajlees @TheLancet This series has been brilliant (and saves me a job of putting together a reading list now for lectures) great article!

[Tom Payne @NeuroPayne]

@ajlees Completely agree, patient’s know what matters to them. Questionnaires rob the patient of the opportunity to contextualize their symptoms properly. Enquiring about further symtpoms of their condition they may not have recognised should be tailored and guided by clinical experience

[NIHR Sheffield Biomedical Research Centre @SheffieldBRC]

📢 Another exciting opportunity to join the NIHR Sheffield BRC as a #ClinicalFellow!

Work on stimulating projects across our Translational #Neuroscience theme.

Get mentored by leading clinicians and scientists.

🔗 Learn more & apply here: https://t.co/1bysPyccoA

[Tom Payne @NeuroPayne]

Nothing makes you realise how fast the last 12 months have flown by more than the annual researchfish submission email. Felt like I only did it last month. Potential to harness this for time travel to the future?

[Tom Payne @NeuroPayne]

@wt_clarke Agree! Needs to begin at undergraduate level and progress through postgraduate study as well. Unviersities need to embed coding in STEM as a core skill at all levels for the future with approriate teaching and support for all

[Tom Payne @NeuroPayne]

As a #DoctorWho fan and scientist this is absolutely brilliant! Maybe I need to start looking at framing all my Parkinson’s research in the context of Doctor Who. Very entertaining read @Richard_D_Riley

[The BMJ @bmj_latest]

A new #DoctorWho episode shown during the festive period, especially on Christmas Day, is associated with lower death rates in the subsequent year across the UK, finds new #ChristmasBMJ study

#DrWho @Richard_D_Riley
https://t.co/6tfxbivjso

[Tom Payne @NeuroPayne]

Really proud to be part of this paper and another big chunk of work from my PhD published! Many thanks to funders @MichaelJFoxOrg and all participants involved!

[Prof Heather Mortiboys @HeatherMortiboy]

It’s paper time! Our paper investigating mitochondria in fibroblasts and MR spectroscopy imaging from the same people with Parkinson’s is out in Brain.
Great work everyone @Toby__Burgess @NeuroPayne @neuroshef

https://t.co/TzjpygDn8O

[Tom Payne @NeuroPayne]

Fantastic paper, congrats!

[The Barker / Williams-Gray Lab @PDandHDLab]

Congrats to all involved! 🙌🏽🎉Neuroinflammation is linked to dementia risk in Parkinson’s disease https://t.co/shfXyHa2iL

[Tom Payne @NeuroPayne]

@MichaelOkun @Penn @PennNeurology Neuropathologically its hard to argue not putting them under the same umbrella. However, there is still some clinical utility to differentiate PD and DLB, if at the least to guide patients and families regarding prognosis and treatment approaches

[Tom Payne @NeuroPayne]

@MarkRCookson1 I both simultaneously agree and feel personally attacked 😂

[Tom Payne @NeuroPayne]

@hamzah2506 Watching many of my peers have to go through this as well, it presents huge challenges to delivering good training both to those individuals and the wider training programme with SpR’s getting pulled in multiple different directions, makes rotas hugely challenging to design

[Tom Payne @NeuroPayne]

@martinw3141 Big fan of that tablecloth!

[Tom Payne @NeuroPayne]

@mr_spectroscopy you may also be interested in this, we used 31P-MRS to assess target engagement of UDCA in the midbrain

[Tom Payne @NeuroPayne]

Very proud that our phase 2 study of UDCA in Parkinson’s has been published by @movedisorder! Many thanks to all participants, collaborators and funders inc. Jon Moulton charity trust and @CureParkinsonsT! @SheffieldBRC @neuroshef @foltynie #parkinsons

https://t.co/lKQgjTd9ZA

[Tom Payne @NeuroPayne]

@MatildeSassani @ee_buckley @am_sheffgenet @bhmullish @claudiamazza5 @l_vangelder

[Michael Okun @MichaelOkun]

New double blind study results of Ursodeoxycholic acid (UDCA) in #parkinsons as a possible mitochondrial rescue agent. Great study by Bandmann and colleagues, 'Midbrain 31P-MRS demonstrated an increase in both Gibbs free energy and inorganic phosphate levels in the UDCA treatment group compared to placebo, reflecting improved ATP hydrolysis. Sensor-based gait analysis indicated a possible improvement of cadence (steps per minute) and other gait parameters in the UDCA group compared to placebo. In contrast, subjective assessment applying the MDS-UPDRS-III failed to detect a difference between treatment groups.' Interesting finding which raise the question as to what outcomes are sensitive enough to detect changes. https://t.co/KpcUPpuM8V

[Tom Payne @NeuroPayne]

@MichaelOkun Many thanks for the kind words! Although MDS-UPDRS can be helpful, I believe we need to move towards more sensitive and objective measures focusing on core features that affect all people with #Parkinsons early on, such as gait rather than very heterogenous features (e.g. tremor)

[Mobilise-D @Mobilise_D]

🚶‍♂️🔍 Join our study on visualizing walking data!

🔑 Share your input! People with PD, MS, COPD, and hip fracture, we need your experiences.

🌟Help us create meaningful visualizations. Register for our short study: https://t.co/hB7T3JZHVI

#WalkingData #PD #MS #COPD #HipFracture